Scientific Content

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers^1,2

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

Early Intervention and Disease Modification in Atopic Dermatitis

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

An easy guide to use Nirsevimab

Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan

Type II Summit 2025

Video Showcasing the Type II Summit 2025

World Epilepsy Day Podcast Ep. 3

World Epilepsy Day Podcast Ep. 2